Interferon-alpha in the treatment of neuroendocrine tumours: effect on glucose tolerance and glucose-stimulated insulin secretion.
To find out whether long term treatment of neuroendocrine tumours with interferon-alpha has any effect on glucose metabolism or insulin secretion. Open study. Department of Surgery, Lund University, Lund, Sweden. Three women and two men, age range 47-72 years. One woman had a pancreatic gastrinoma, the others midgut carcinoids, and all had multiple liver metastases. Intravenous and oral glucose challenges (separated by at least a week) before treatment, and then yearly for three years. Changes in plasma insulin and blood glucose concentrations. Neither the basal concentrations of plasma insulin or blood glucose nor the responses to the glucose challenges changed during the three year period. Long term treatment with interferon-alpha has no obvious adverse effects on glucose tolerance or insulin secretion.